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Abstract
Background
Insulin-like growth factor-1(IGF-1) has a multitude of effects besides cell growth and metab-
olism. Reports also indicate anti-inflammatory and antioxidative effects. The concentrations
of IGF-1 decrease with age and during inflammation. As selenium and coenzyme Q10 are
involved in both the antioxidative defense and the inflammatory response, the present study
aimed to examine the effects of supplementation with selenium and coenzyme Q10 on con-
centrations of IGF-1 and its binding protein IGFBP-1 in a population showing reduced car-
diovascular mortality following such supplementation.
Methods
215 elderly individuals were included and given the intervention for four years. A clinical
examination was performed and blood samples were taken at the start and after 48 months.
Evaluations of IGF-1, the age adjusted IGF-1 SD score and IGFBP-1 were performed using
group mean values, and repeated measures of variance.
Findings
After supplementation with selenium and coenzyme Q10, applying group mean evaluations,
significantly higher IGF-1 and IGF-1 SD scores could be seen in the active treatment group,
whereas a decrease in concentration could be seen of the same biomarkers in the placebo
group.
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Applying the repeated measures of variance evaluations, the same significant increase
in concentrations of IGF-1 (F = 68; P>0.0001), IGF-1 SD score (F = 29; P<0.0001) and
of IGFBP-1 (F = 6.88; P = 0.009) could be seen, indicating the effect of selenium and co-
enzyme Q10 also on the expression of IGF-1 as one of the mechanistic effects of the
intervention.
Conclusion
Supplementation with selenium and coenzyme Q10 over four years resulted in increased
levels of IGF-1 and the postprandial IGFBP-1, and an increase in the age-corrected IGF-1
SD score, compared with placebo. The effects could be part of the mechanistic explanation
behind the surprisingly positive clinical effects on cardiovascular morbidity and mortality
reported earlier. However, as the effects of IGF-1 are complex, more research on the result
of intervention with selenium and coenzyme Q10 is needed.
Introduction
Circulating insulin-like growth factor-1 (IGF-1) is mainly produced in the liver as a response
to stimulus from the growth hormone [1], but is also produced locally in different tissues in
the body. It is a 70 amino acid polypeptide with a weight of 7.6 kDa [2], and there are six bind-
ing proteins that modulate the effects of IGF-1 [3]. It has anabolic effects in adults, with pleio-
tropic effects on both cell growth and metabolism. Of the multitude of effects described, it has
been reported that overexpression of IGF-1 diminishes myocyte necrosis and apoptosis in my-
ocardial infraction in a mouse model [4]. It has also been demonstrated that there is reduced
cardiac myocyte atrophy as a result of ischemia in those with high levels of IGF-1 [5]. IGF-1
also has anti-inflammatory effects and decreases the concentration of pro-inflammatory cyto-
kines [6, 7]. In the normal population there is a well-known decrease of the IGF-1 levels with
increasing age [8]. Therefore,
In patients with ischemic heart disease, the amount of coronary calcium deposits has been
reported to be inversely associated with the level of IGF-1 [9], and in several studies a low
level of IGF-1 has been associated with increased risk of ischemic heart disease or myocardial
infarction, as seen in both human and animal models [10–12]. In elderly men, however, Carl-
zon et al. demonstrated increased risk of cardiovascular events both in those with high and low
IGF-1 levels [13].
Scharin Ta¨ng et al. reported interesting data from a mouse model indicating that a greater
cardiac left ventricular volume and decreased cardiac function could be demonstrated in those
with induced absence of IGF-1 [14]. In humans, Andreassen et al. found that low levels of
IGF-1 could act as a predictor for heart failure progression and cardiovascular mortality [15].
This has also been demonstrated by others [16, 17].
Thus, there is a clear clinical association between decreased concentration of IGF-1 and
disease also in the elderly, as can be seen in the literature [10, 15, 17–21]. As described in the
literature, the IGF-binding protein-1 (IGFBP-1) is also associated with cardiovascular disease
[17,18]. In previous studies we have shown that supplementation with selenium and coenzyme
Q10 in an elderly healthy Swedish population reduced cardiovascular mortality, improved
cardiac function [22], and decreased oxidative stress[23] and inflammation [24]. A possible
mechanism behind these effects may be an influence on IGF concentrations. As our study pop-
ulation had a mean age of 78 years and the IGF concentration decreases with age [25], we
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hypothesized that those randomized to selenium and coenzyme Q10 would preserve their high
IGF concentration, whereas the placebo group would have a decrease in IGF concentration.
The aim of this sub study was to investigate a possible influence of supplementation with
selenium and coenzyme Q10 for four years on IGF-1 and IGFBP-1 in an elderly healthy Swed-
ish population.
Material and methods
The design of the main study has been published elsewhere [22]. In brief, 443 elderly healthy
participants living in a rural municipality in the south of Sweden were randomized to dietary
supplementation of 200 mg/day of coenzyme Q10 capsules (Bio-Quinon 100 mg B.I.D,
Pharma Nord, Vejle, Denmark) and 200 μg/day of organic selenium yeast tablets (SelenoPre-
cise 200 μg, Pharma Nord, Vejle, Denmark), or a similar placebo. The study supplementation
was taken in addition to regular medication. The participants were examined by one of three
experienced cardiologists. A new clinical history was recorded, and a clinical examination was
performed, including resting blood pressure, assessment of New York Heart Association func-
tional class (NYHA class) as well as ECG and Doppler- echocardiography. Echocardiographi-
cal examinations were performed with the participant in the left lateral position. The ejection
fraction (EF) readings were categorized into four classes with interclass limits placed at 30%,
40% and 50% [26, 27]. Normal systolic function was defined as EF 50%, while severely
impaired systolic function was defined as EF< 30%.
As the intervention time was unusually long (48 months) only 221 participants completed
the study, 64 died during the total intervention time, and 129 (29.1%) decided not to complete
the study. The reasons for the latter have been presented in detail in the main publication, but
the main reason was that there were too many tablets to take [22]. The first participant was
included in January 2003, and the last participant concluded the study in February 2010. Out
of the total study population, 215 participants were analyzed regarding IGF-1, the age-cor-
rected values of IGF-1 (IGF-1 SD) based on the standard deviation of the mean value based on
247 healthy individuals [28, 29], and the IGF-binding protein 1 (IGFBP-1), which is presented
in this report. Of these, 117 had previously been randomized to active treatment (supplemen-
tation with selenium and Q10) and 98 to placebo. Thirteen participants missed delivering the
final blood samples for the IGF-1 evaluation.
Written, informed consent was obtained from all patients. The study was approved by the
Regional Ethical Committee in Linko¨ping, Sweden (Diary no. 03–176), and conforms to the
ethical guidelines of the 1975 Declaration of Helsinki. This study was registered at Clinical-
trials.gov, and has the identifier NCT01443780
Biochemical analyses
All blood samples were obtained while the patients were at rest in a supine position. The blood
samples were collected in plastic vials containing EDTA (ethylenediamine tetracetic acid). The
vials were placed on ice before chilled centrifugation at 3000g, and then frozen at -70˚C. No
sample was thawed more than twice.
IGF-1 concentrations in plasma were determined by an in-house RIA after separation of
the different IGFs from IGFBPs by acid ethanol extraction and cryoprecipitation. To minimize
interference from the remaining IGFBPs, des (1–3) IGF-1 was used as a radioligand [30]. The
intra- and inter-assay coefficients of variation (CV) were 4% and 11%, respectively. Plasma
concentrations of IGF-1 are age-dependent, decreasing with age, thus IGF-1 values are also
expressed as standard scores (SD scores) calculated from the regression of the values of two
populations of healthy adult subjects [29, 31–34].
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IGFBP-1 concentrations were determined by an in-house RIA using the method of Po´voa
et al. [35]. The sensitivity of the RIA was 3 μg/L and the intra- and inter-assays CV were 3%
and 10%, respectively.
Statistical methods
Descriptive data are presented as percentages or mean ± standard deviation (SD). A student’s
unpaired two-sided t-test was used for continuous variables and the Chi-square test was used
for analysis of one discrete variable. As the dataset demonstrated a slight non-Gaussian dis-
tribution, the dataset was transformed in order to obtain a normal distribution, which was
controlled through Kolmogorov-Smirnov´s test. Transformed data were used in the t-test
evaluations as this evaluation is more sensitive to a non-normal distribution of data. As the
ANOVA algorithm can handle a slight non-Gaussian distribution, non-transformed data were
applied in the repeated measures of variance evaluation.
Evaluation of the effects of treatment were based both on group mean values, but also on
use of a repeated measures of variance analysis where the values of the individual participant
were identified during the two different measured time points. P-values < 0.05 were consid-
ered significant, based on a two-sided evaluation. All data were analyzed using standard soft-
ware (Statistica v. 13.2, Dell Inc, Tulsa, OK).
Results
Study population
The study population of this study consisted of 215 individuals, of which 117 had been given
active supplementation consisting of selenium and coenzyme Q10 combined, and 98 individu-
als had been randomized to placebo (Table 1, Fig 1).
Of the study population, 113 were females, and 102 were males. In the population, about
71% had been diagnosed with hypertension, about 18% had ischemic heart disease, 17% had
diabetes, and 5% had an impaired systolic cardiac function defined as EF<40%. The different
covariates were well balanced between the active versus the placebo group, and it could also be
seen that the subgroup analyzed was representative of the original study population consisting
of 443 individuals (Table 1).
At start of the study we were able to demonstrate a trend for higher IGF-1 levels in those
already on treatment with ACE-inhibitors, or AII blockers (t = 1.83; P = 0.068), a result that
could be expected to be significant if a larger study group had been included. This concurs
with results from Maggio et al. including elderly patients on treatment with ACE-inhibitors
[36].
Evaluations of the IGF-1, IGF-1 SD and IGFBP-1 levels have been performed in relation to
basal serum selenium concentration, which varied from 21.4 μg/L Se to 158 μg/L Se, with a
median of 67.1 μg/L Se. No significant associations could be found.
IGF-1 and intervention with selenium and coenzyme Q10
At the start of the intervention the serum levels of IGF-1 in the subgroups of those given sele-
nium and coenzyme Q10 combined were not significantly different from values in those given
the placebo (t = 1.82; P = 0.06) (Fig 2). However, at the end of the intervention period a signifi-
cantly higher serum level of IGF-1 could be seen in the active treatment group compared with
the placebo group (183 vs. 166 microgram/L; t = 5.78; P<0.0001). A significant increase in the
serum IGF-1 was observed in the active treatment group (from 154 to 183 microgram/L;
IGF-1 increases by intervention with selen and coenzyme Q10
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t = 4.38; P<0.0001), whereas a decrease was seen in the placebo group (166 vs. 144 micro-
gram/L; t = 3.43; P = 0.0007).
However, as group mean values do not necessarily express the individual change of levels,
repeated measures of variance were also performed. Applying repeated measures of variance,
using group (active and placebo) and follow-up (baseline and 48 months) a significant effect
on serum levels of IGF-1 (i.e. groupfollow-up interaction),F = 68; P<0.0001 could be seen,
favoring those receiving selenium and coenzyme Q10. Thus, an increase in IGF-1 concentra-
tion in those receiving the active substance and a decrease in those given the placebo could be
seen (Fig 3.)
Applying an age-corrected score of IGF-1, the IGF-1 SD, the same result was obtained; at
the start of the intervention no statistical difference in score between the active treatment
group and the placebo group could be seen (t = 0.06; P = 0.96) (Fig 4). However, at the end of
the intervention, a highly significant difference could be noted between the groups, with a
higher score in the active treatment group (t = 3.11; P = 0.002). In the active treatment group,
a tendency to increase in score was noted during the intervention (from 1.22 to 1.58; P = 0.05),
whereas a non-significant decrease was noted in the placebo group (from 1.26 to 0.95; P =
0.16). Applying the repeated measure of variance methodology, as reported above, a highly sig-
nificant effect on IGF-1 SD could be demonstrated (F = 29; P<0.0001)(Fig 5.).
In order to evaluate the influence of the basal serum selenium concentration on the
response to supplementation of selenium and coenzyme Q10 as seen in the concentration of
IGF-1, we performed evaluations of the subgroup having the lowest quartile of basal selenium
concentration, and compared the response of IGF-1 with those having the highest quartile (Fig
6A and 6B). It could be seen that the response to supplementation with selenium on IGF-1
Table 1. Basal characteristics of the study population divided into active treatment and placebo, as compared to the total study population.
Active treatment P-value Placebo Total study population
n 117 98 443
Age years mean (SD) 76.1 (3.1) 0.96 76.2 (3.1) 77.1 (3.5)
History
Smokers n (%) 8 (6.8) 0.53 9 (7.7) 41 (9.3)
Diabetes n (%) 20 (17.1) 0.96 17 (14.5) 95 (21.4)
Hypertension n (%) 81 (69.2) 0.61 71 (72.4) 326 (73.6)
IHD n (%) 22 (18.8) 0.64 16 (16.3) 100 (22.6)
NYHA class I n (%) 72 (61.5) 0.61 57 (58.2) 226 (51.0)
NYHA class II n (%) 28 (23.9) 0.27 30 (30.6) 125 (28.2)
NYHA class III n (%) 17 (14.5) 0.34 10 (10.2) 88 (19.9)
NYHA class IV n (%) 0 0 0
Unclassified NYHA n (%) 0 1 4 (1.0)
Medications
ACEI n (%) 16 (13.7) 0.90 14 (14.3) 89 (20.1)
ARB n (%) 3 (2.6) 7 (7.1) 23 (5.2)
Betablockers n (%) 42 (36.0) 0.73 33 (33.7) 153 (34.5)
Digitalis n (%) 5 (4.3) 1 (1.0) 22 (5.0)
Diuretics n (%) 37 (31.6) 0.87 33 (33.7) 158 (35.7)
Statins n (%) 27 (23.1) 0.40 18 (18.4) 96 (21.7)
Examinations
EF<40% n (%) 7 (6.0) 0.53 4 (4.1) 33 (7.4)
Note: ARB; Angiotension receptor blockers; EF: Ejection fraction; IHD; Ischemic heart disease; NYHA: New York Heart Association functional class
https://doi.org/10.1371/journal.pone.0178614.t001
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concentration was significantly higher in those where there was a selenium deficiency com-
pared with those with no, or little deficiency. This is in line with previous reports.
Estimated active form of IGF-1
In the literature, the use of the ratio of IGF-1/IGFBP-1 as a measure of the active form of IGF-
1 has been proposed [37]. A decline in this ratio could be reported in the placebo group during
the intervention time (9.72 to 6.31; t = 2.37; P = 0.019), whereas in the active treatment group a
trend towards a decline during the intervention time could be seen (10.13 to 8.97; t = 2.00;
P = 0.05), and comparing the ratios of IGF-1/IGFBP-1 between the active and the placebo
groups after the intervention a significant difference could be reported (8.97 versus 6.31;
t = 2.18; P = 0.04).
IGF-binding protein-1 and intervention with selenium and coenzyme Q10
The plasma concentrations of one of the six IGF-binding proteins, IGFBP-1, were determined
2–3 hours after a meal. At the start of the intervention, no statistical difference in mean con-
centrations between the active treatment group, and the placebo group could be noted (30 vs.
32 microgram/L; P = 0.25) (Fig 7). At the end of the intervention, no significant difference
could be noted (44 vs. 37 microgram/L; P = 0.45). However, applying the repeated measure of
variance methodology, a significant difference could be demonstrated (F = 6.88; P = 0.009),
with a higher increase in the IGFBP-1 concentration in the active group compared with the
active treatment group (Fig 8).
We also examined the participants having a concentration of IGFBP-1 in the highest quar-
tile (Q4) and compared the number in the active treatment group with that of the placebo
group. No difference in the numbers of participants in Q4 could be seen at the start of the
intervention (24/98 versus 29/117: P = 0.96). However, after the intervention, compared to the
Fig 1. CONSORT flow chart of the study.
https://doi.org/10.1371/journal.pone.0178614.g001
Fig 2. IGF-1 in the active and the placebo groups at the inclusion compared to after 48 months.
https://doi.org/10.1371/journal.pone.0178614.g002
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placebo group a significantly higher number of participants could be seen in Q4 of IGFBP-1
from the active treatment group (16/98 versus 36/117; χ2 = 6.07; P = 0.014).
Discussion
In the present study we found raised concentrations of IGF-1 and IGF-binding protein-1 in
the participants receiving the active intervention, upon the follow-up investigation of the pop-
ulation at the end of the study period. In contrast, we observed decreasing concentrations in
those receiving the placebo, which was as expected in this group of aged Swedish individuals
[8]. The increase in IGF-1in the supplemented group compared to the placebo group may be
connected to the earlier reported decrease in both inflammatory activity and oxidative stress
[6] possibly caused by supplemental selenium [38].
As the intervention time in our study was unusually long, four years, and the study pop-
ulation consisted of elderly individuals with a relatively low basal selenium status (41), we
hypothesized that there would be a decrease in the levels of IGF-1 in the placebo group and
preserved levels in those given active supplementation. In our post hoc analysis, using repeated
Fig 3. IGF-1 concentration in the active treatment and the placebo groups at the start and at the end of the intervention.
https://doi.org/10.1371/journal.pone.0178614.g003
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measurement analyses and an age-corrected dataset, we found raised concentrations of IGF-1
and IGF-binding protein-1 resulting from the active intervention in contrast to the decreasing
levels in those receiving the placebo.
In the literature, several pleiotropic effects of IGF-1 have been reported, including antia-
poptotic effects [39], and antioxidative effects that could delay atherosclerosis [40, 41]. It has
also been shown that IGF-1 increases the circulating number of endothelial progenitor cells
that might correct the age-dependent deterioration of the cells [42]. The raised levels of IGF-1
resulting from the intervention, might decrease inflammation and oxidative stress, and pro-
mote formation of nitric oxide, and thus relax arterial smooth muscle cells, reduce platelet
adhesion and decrease the level of oxidized LDL cholesterol [43–45]. Also, important informa-
tion was presented by Lohr et al. showing an inverse relationship between IGF-1 and the
inflammation biomarker hsCRP [46].
However, upon relating IGF-1, IGF-1 SD and IGFBP-1 levels at baseline to the basal levels
of selenium, no significant correlations were seen. Here, it should be noted that the present
population was relatively homogenous with respect to selenium status, with median serum
selenium of 67.1 μg/L, all individual values being below a proposed optimum of 90 μg/L [47].
In contrast to our finding, Maggio et al. have shown an independent and positive association
between selenium levels and IGF-1 in an elderly community-living population comparable to
the population examined in the present study, but with a higher selenium status, mean 113 μg/
L [48]. By using a mouse model and low doses of selenite, Ren et al. observed both an increased
growth and expression of serum IGF-1R and antiapoptotic effects. With higher toxic doses of
selenite, growth inhibition, decreased IGF-1R and apoptosis were seen. Similarly, low doses of
selenite induced IGF-1R in osteoblasts in vitro whereas with high doses the opposite occurred
[49]. Here, the positive effect of selenium might be mediated via an effect on the IGF-1R rather
than changes in IGF-1 levels.
When expressing the free and active fraction of IGF-1 as the ratio IGF-1/IGFBP-1, we
found that the intervention caused a significantly attenuated decline in the active form of IGF-
1. IGFBP-1 was determined after a meal, and we expected its postprandial concentrations to
Fig 4. IGF-1 SD score in the active and the placebo groups at inclusion compared to after 48 months.
https://doi.org/10.1371/journal.pone.0178614.g004
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be low due to suppressed expression following the insulin response [33, 50]. The higher
IGFBP-1 levels seen in those treated with CoQ10 and selenium suggest a decreased insulin
response to the meal due to improved insulin sensitivity. The increased IGF-1 levels induce
improved insulin sensitivity in accordance with previous studies showing that antioxidants
can improve insulin sensitivity [51, 52]. Our results indicating increased insulin sensitivity are
interesting in relation to previous concerns about the possibility that selenium supplementa-
tion should cause an increased risk of diabetes [53]. In the present study population, plasma
selenium remained well below the upper limit of the considered optimal zone (EFSA, 2014).
Furthermore, no increased risk for diabetes (HR:1.09; 95% CI: 0.99–1.20) was reported in one
of the biggest meta-analyses (n = 20.294) evaluating the risk for diabetes during selenium sup-
plementation, and also including participants from the US, [54]. Moreover, improved insulin
sensitivity may also reduce mortality in old people [55]. This supports the results presented
above indicating that selenium and coenzyme Q10 have fundamental effects in the different
areas where IGF-1 exerts its actions. In European populations with low basal selenium values
our observations suggest that combined supplementation with selenium and coenzyme Q10
may evoke a multitude of effects, including increased IGF-1 and improved insulin sensitivity,
which might be among the underlying mechanisms for the positive clinical health effects
reported previously.
Fig 5. IGF-1 SD score at inclusion on the active treatment and in the placebo groups at the start and at the end of the
intervention.
https://doi.org/10.1371/journal.pone.0178614.g005
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Clinical implications
The present subgroup analysis is one of the various efforts to better understand the mecha-
nisms behind the positive clinical results, which include better health-related quality of life
[56], better cardiac function[22], and reduced cardiovascular mortality [22] resulting from the
intervention with selenium and coenzyme Q10 previously reported. Thus, the analysis pro-
vides important data for the clinician, at least in areas with a low basal selenium intake in the
general population. Of particular interest here is that the intervention resulted in reduced car-
diovascular mortality after 10 years, despite the intervention period lasting only fours [57]. We
have also reported less inflammatory activity and less oxidative stress as a result of the inter-
vention, as seen in the biomarkers sP-selectin and hs-CRP [24] and the biomarkers copeptin,
and MR-proADM, respectively [23].
It is tempting to argue that in areas with low selenium content in the soil, or where residents
have low daily intake of selenium, a moderate supplementation with selenium and coenzyme
Q10 will have positive effects, including effects on the levels of IGF-1 in the elderly, as part of
the total clinical response, reported above.
Limitations and strengths
This is a small post hoc study including elderly participants; thus it is not possible at present to
extrapolate our results into other age strata. Also, the population was ethnically homogenous,
so caution should be used when interpreting the results.
The strength of the report is that the study population was extensively evaluated, and the
positive results regarding IGF-1 accord very well with the positive clinical and laboratory
results reported earlier.
Fig 6. Response to IGF-1 of supplementation with selenium and coenzyme Q10 in those with a
basal selenium concentration in the lowest quartile (Fig 6a), and in those with a basal selenium
concentration in the highest quartile (Fig 6b).
https://doi.org/10.1371/journal.pone.0178614.g006
Fig 7. IGFBP-1 in the active and the placebo groups at inclusion compared with after 48 months.
https://doi.org/10.1371/journal.pone.0178614.g007
IGF-1 increases by intervention with selen and coenzyme Q10
PLOS ONE | https://doi.org/10.1371/journal.pone.0178614 June 13, 2017 12 / 17
Conclusions
IGF-1 has important functions in both cell growth and metabolism, but also in inflammation
and antioxidative defense. A decrease in IGF-1 has been reported with increased age, and also
in advanced cardiovascular disease.
From our studies on an elderly healthy Swedish population, we have reported in previous
publications that more than 90% had suboptimal selenium status [58]. The present evaluation
shows that intervention with selenium and coenzyme Q10 resulted in increased levels of IGF-
1, as well as in the age-corrected value of IGF-1, and also in the postprandial IGF-binding pro-
tein-1 indicative of improved insulin sensitivity. These findings may represent important
information on the mechanisms behind the positive clinical effects on cardiovascular morbid-
ity and mortality of supplementation with selenium and coenzyme Q10.
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Fig 8. IGFBP-1 concentration in the active treatment and the placebo groups at the start and at the end of the intervention.
https://doi.org/10.1371/journal.pone.0178614.g008
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